文献速递神经免疫

探索血浆脂质与他汀干预在多发性硬化风险与严重程度中的作用:一项孟德尔随机化研究

Exploring the Role of Plasma Lipids and Statin Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study.
PubMed 文献 · Neurology · 2023-09-01

该研究采用两样本孟德尔随机化方法,利用GLGC、eQTLGen和IMSGC的汇总统计量,探讨血脂及他汀类药物的胆固醇依赖与非依赖效应在多发性硬化(MS)风险和严重程度中的因果作用。结果显示,遗传预测的RAC2(胆固醇非依赖通路成员)与MS风险降低相关(OR 0.86),而终生较高的HDL-C与MS风险增加相关(OR 1.14),未发现LDL-C、TG或遗传模拟他汀对MS严重程度的因果证据。

要点

  • 遗传预测的RAC2与MS风险降低相关(OR 0.86,95%CI 0.78-0.95)。
  • 终生较高的HDL-C与MS风险增加相关(OR 1.14,95%CI 1.04-1.26)。
  • 未发现LDL-C、TG或遗传模拟他汀对MS严重程度的因果证据。

核心结论

  • RAC2可能是MS风险的遗传修饰因子,他汀可能通过胆固醇非依赖通路(即RAC2相关机制)降低MS风险。
  • 孟德尔随机化分析支持HDL-C对MS风险的因果效应。

研究设计与样本

  • 两样本孟德尔随机化研究,使用GLGC(n=188,577)、eQTLGen(n=31,684)和IMSGC(MS风险n=41,505;MS严重程度n=7,069)的汇总统计量。

主要发现

  • 遗传预测的RAC2与MS风险降低相关(OR 0.86 [95% CI 0.78-0.95],p-value 3.80E-03)。
  • 未发现LDL-C和胆固醇生物合成通路成员对MS风险的因果作用证据。
  • 终生较高的HDL-C与MS风险增加相关(OR 1.14 [95% CI 1.04-1.26],p-value 7.94E-03),TG无此关联。
  • 未发现血脂和遗传模拟他汀对MS严重程度的因果作用证据。
  • 未发现MS风险与血脂之间的反向因果关系证据。

临床怎么用

  • 作者认为他汀可能通过胆固醇非依赖通路(即RAC2相关机制)降低MS风险。
  • 孟德尔随机化分析支持HDL-C对MS风险的因果效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: There has been considerable interest in statins because of their pleiotropic effects beyond their lipid-lowering properties. Many of these pleiotropic effects are predominantly ascribed to Rho small guanosine triphosphatases (Rho GTPases) proteins. We aimed to genetically investigate the role of lipids and statin interventions on multiple sclerosis (MS) risk and severity. METHOD: We used two-sample Mendelian randomization (MR) to investigate (1) the causal role of genetically mimic both cholesterol-dependent (through low-density lipoprotein cholesterol (LDL-C) and cholesterol biosynthesis pathway) and cholesterol-independent (through Rho GTPases) effects of statins on MS risk and MS severity, (2) the causal link between lipids (high-density lipoprotein cholesterol [HDL-C] and triglycerides [TG]) levels and MS risk and severity, and (3) the reverse causation between lipid fractions and MS risk. We used summary statistics from the Global Lipids Genetics Consortium (GLGC), eQTLGen Consortium, and the International MS Genetics Consortium (IMSGC) for lipids, expression quantitative trait loci, and MS, respectively (GLGC: n = 188,577; eQTLGen: n = 31,684; IMSGC (MS risk): n = 41,505; IMSGC (MS severity): n = 7,069). RESULTS: The results of MR using the inverse-variance weighted method show that genetically predicted RAC2, a member of cholesterol-independent pathway (OR 0.86 [95% CI 0.78-0.95], p-value 3.80E-03), is implicated causally in reducing MS risk. We found no evidence for the causal role of LDL-C and the member of cholesterol biosynthesis pathway on MS risk. The MR results also show that lifelong higher HDL-C (OR 1.14 [95% CI 1.04-1.26], p-value 7.94E-03) increases MS risk but TG was not. Furthermore, we found no evidence for the causal role of lipids and genetically mimicked statins on MS severity. There is no evidence of reverse causation between MS risk and lipids. DISCUSSION: Evidence from this study suggests that RAC2 is a genetic modifier of MS risk. Because RAC2 has been reported to mediate some of the pleiotropic effects of statins, we suggest that statins may reduce MS risk through a cholesterol-independent pathway (that is, RAC2-related mechanism(s)). MR analyses also support a causal effect of HDL-C on MS risk.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Almramhi MM, Finan C, Storm CS, et al. Exploring the Role of Plasma Lipids and Statin Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study. Neurology. 2023. PMID: 37657941. doi:10.1212/WNL.0000000000207777

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。